Integra Lifesciences Holdings (IART) Common Equity (2009 - 2026)

Integra Lifesciences Holdings has disclosed Common Equity across 18 years of filings, most recently posting $1.0 billion for Q2 2026.

• In Q2 2026, Common Equity changed 0.45% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $1.0 billion (changed 0.45% YoY), while the FY2025 annual figure was $1.0 billion, down 32.47% from the prior year.
• Common Equity came in at $1.0 billion for Q2 2026 at Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
• Average Common Equity over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2023.
• Year-over-year, Common Equity grew 7.1% in 2022 and tumbled 32.47% in 2025.
• Over 5 years, Common Equity stood at $1.8 billion in 2022, then declined by 12.0% to $1.6 billion in 2023, then slipped by 2.68% to $1.5 billion in 2024, then plunged by 32.47% to $1.0 billion in 2025, then declined by 0.01% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.0 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.0 billion in Q4 2025.